Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
Jasper Therapeutics, Inc. JSPR
$1.56
+$0.07 (4.36%)
На 18:05, 12 мая 2023
+92.31%
Потенциал через год
Ключевые показатели
-
Marketcap
160461765.00000000
-
week52high
3.80
-
week52low
0.39
-
Revenue
0
-
P/E TTM
-2
-
Beta
1.99016300
-
EPS
-0.98000000
-
Last Dividend
0.00000000
-
Next Earnings Date
10 мая 2023 г. в 10:59
Описание компании
Jasper Therapeutics, Inc., a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. It focuses on the development and commercialization of conditioning agents and stem cell engineering to allow expanded use of stem cell transplantation and ex vivo gene therapy, a technique in which genetic manipulation of cells is performed outside the body prior to transplantation. The company's lead product candidate is JSP191, which is in clinical development as a conditioning antibody that clears hematopoietic stem cells from bone marrow in patients prior to undergoing allogeneic stem cell therapy or stem cell gene therapy. It is also developing engineered hematopoietic stem cells product candidates to overcome key limitations of allogeneic and autologous gene-edited stem cell grafts. The company is based in Redwood City, California.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| Credit Suisse | Outperform | Outperform | 13 июл 2022 г. |
| Credit Suisse | Outperform | Outperform | 13 мая 2022 г. |
| Cantor Fitzgerald | Overweight | 28 февр 2022 г. | |
| Credit Suisse | Outperform | Outperform | 25 февр 2022 г. |
| Credit Suisse | Outperform | 08 ноя 2021 г. | |
| Oppenheimer | Outperform | Outperform | 14 ноя 2022 г. |
| EF Hutton | Buy | 01 ноя 2022 г. | |
| EF Hutton | Buy | Buy | 11 янв 2023 г. |
| Credit Suisse | Outperform | Outperform | 11 янв 2023 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
компании
Insider Summary
Insider Summary
| Reporting Name | Acquistion/Disposition | Owned | Transacted | Transaction Date |
|---|---|---|---|---|
| MARTELL RON | A | 1093831 | 1093831 | 02 февр 2023 г. |
| Carlyle Group Inc. | A | 8761891 | 3133333 | 27 янв 2023 г. |
| ROCHE HOLDING LTD | D | 4549606 | 75000 | 25 янв 2023 г. |
| MARTELL RON | A | 506250 | 506250 | 12 окт 2022 г. |
| EMSTER KURT VON | A | 30250 | 30250 | 12 окт 2022 г. |
| Klein Lawrence Otto | A | 24500 | 24500 | 12 окт 2022 г. |
| Shizuru Judith Anne | A | 1159012 | 29500 | 12 окт 2022 г. |
| Lis William | A | 69986 | 29500 | 12 окт 2022 г. |
| Nolet Chris | A | 32500 | 32500 | 12 окт 2022 г. |
| Mahal Jeetinder Singh | A | 324349 | 214722 | 12 окт 2022 г. |
Новостная лента
Penny Stocks To Buy Now? 7 To Watch With Big News this Week
PennyStocks
26 янв 2023 г. в 09:28
Penny stocks with news that has turned heads in the stock market this week. The post Penny Stocks To Buy Now?
4 Penny Stocks To Watch With Big News This Week
PennyStocks
25 янв 2023 г. в 12:10
Penny stocks to watch after big news this week. The post 4 Penny Stocks To Watch With Big News This Week appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
Mid-January Penny Stocks Trading Tips
PennyStocks
17 янв 2023 г. в 06:00
Trading penny stocks in mid-January? Use these tips The post Mid-January Penny Stocks Trading Tips appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
How to Avoid Losing Money With Penny Stocks in a Volatile Market
PennyStocks
14 янв 2023 г. в 11:00
Can these tips help you to avoid losing money with penny stocks The post How to Avoid Losing Money With Penny Stocks in a Volatile Market appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
Why Is Jasper Therapeutics (JSPR) Stock Up 50% Today?
InvestorPlace
13 янв 2023 г. в 11:24
There's no denying that Jasper Therapeutics (NASDAQ: JSPR ) stock investors are in a good mood today. They're clearly celebrating the announcement of Jasper's Phase 1 data for briquilimab in the treatment of certain types of blood disease.